Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$816.65 USD

816.65
879,559

-12.78 (-1.54%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $816.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses

Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.

    Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y

    Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.

      Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Down Y/Y

      Bayer AG's (BAYRY) fourth-quarter 2017 core earnings per share from continuing operations beat estimates.

        Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4

        Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.

          Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y

          Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.

            Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y

            Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.

              AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues

              AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.

                Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus

                Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.

                  Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

                  Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.

                    Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down

                    Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.

                      Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4

                      Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.

                        Is a Beat in Store for Adverum (ADVM) This Earnings Season?

                        Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.

                          BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

                          BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

                            Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

                            Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.

                              Novavax (NVAX) in Focus: Stock Moves 8.3% Higher

                              The shares of Novavax (NVAX) rose over 8% yesterday.

                                The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

                                The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

                                  Mark Vickery headshot

                                  Top Research Reports for Novo Nordisk, TJX Companies & Cigna

                                  Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), TJX Companies (TJX) and Cigna (CI).

                                    Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

                                    Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

                                      Ekta Bagri headshot

                                      Regeneron (REGN) Tops Q4 Earnings & Sales

                                      Regeneron???s fourth-quarter 2017 earnings (excluding one-time charges) and sales topped expectations.

                                        Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

                                        Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

                                          REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

                                          Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

                                            Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?

                                            With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.

                                              Arpita Dutt headshot

                                              Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February

                                              Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.

                                                Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                                                Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                                                  Ophthotech Begins Phase II Zimura Study in Stargardt Disease

                                                  Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.